ArticleJournal of neuro-oncology2026
Magnetic resonance imaging-based biodistribution of theranostic AGuIX nanoparticles in the NANORAD 2 clinical trial for brain metastases.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAGuIX nanoparticles are promising theranostic agents that selectively accumulate in brain metastases via the enhanced permeability and retention effect, potentially improving radiotherapy efficacy. This ancillary analysis of the NANORAD2 trial investigates AGuIX biodistribution in patients with multiple brain metastases undergoing whole-brain radiotherapy (WBRT).
methodsSignal enhancement (SE) maps, quantifying the relative increase in T1-weighted MRI signal intensity due to AGuIX accumulation, were generated from pre- and post-injection scans of 11 patients receiving three weekly AGuIX injections (100 mg/kg) prior to radiotherapy. SE values were measured in 14 regions of interest at one hour post-injection in all patients (n = 11), at four hours in a subset (n = 4) to assess early clearance, and at one hour after the third injection (n = 7) to evaluate long-term accumulation.
resultsAt one hour post-first injection, full-volume brain metastases showed marked SE elevation to 54.1 ± 29.5% (mean and standard deviation, n = 208 metastases), while surrounding organs exhibited transient SE (especially pituitary gland) that declined at four hours (all SE values < limit of detection, n = 11). At four hours, mean metastatic SE decreased from 33.8 ± 18.4% to 18.8 ± 16.6% (n = 54, p < 10− 10), indicating partial clearance. After three weekly injections, mean metastatic SE at one hour remained stable comparing to first injection (from 63.0% to 64.8%, n = 132), demonstrating complete inter-dose clearance with no cumulative accumulation detectable by MRI.
conclusionThis study confirms selective AGuIX accumulation in brain metastases with favorable clearance kinetics, supporting radiotherapy delivery four hours post-injection to optimize therapeutic ratio while minimizing off-target exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.